Abstract / Summary
Obesity is a chronic disease that is a major risk factor for serious, long-term health complications. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of pharmacotherapies that are highly effective in the treatment of obesity, producing weight loss of 15-20% or greater in clinical trials. Current clinical guidance recommends continued therapy to sustain these benefits; however, barriers including cost, limited access, and adverse effects may inhibit long-term use and contribute to high discontinuation rates. Abrupt discontinuation of GLP-1RA therapy is problematic as it is associated with significant weight regain and reversal of cardiometabolic improvements. Given the challenges associated with prolonged treatment, there is a critical need to develop evidence-based strategies that support patients who reduce or discontinue GLP-1RA therapy. This paper explores the scientific premise for structured dose-reduction approaches, coupled with behavioral and psychological interventions, to promote durable weight-loss maintenance following GLP-1RA therapy.